Nature Reviews Drug Discovery

Teague S. J. (2003). Implications of protein flexibility for drug discovery. Nature Reviews Drug Discovery 2 527-541. 

Gershell LJ, Miller LA. Emerging unscathed Nature Reviews Drug Discovery 2002 1 739. 

Federsel, H.J. (2005) Asymmetry on Large Scale The Roadmap to Stereoselective Processes. Nature Reviews Drug Discovery, 4, 685-697. 

Dohrenwend, Bruce P., Itzhak Levav, Patrick E. Shrout, Sharon Schwartz, Guedalia Naveh, Bruce G. Link, Andrew E. Skodol and Ann Stueve, Socioeconomic Status and Psychiatric Disorders The Causation-Selection Issue , Science 255, no. 5047 (1992) 946-52 Donaldson, Liam, At Least Five a Week Evidence on the Impact of Physical Activity and Its Relationship to Health. A Report from the Chief Medical Officer , Department of Health, 2004 Editorial, A Double-Edged Sword , Nature Reviews Drug Discovery 7 (2008) 275... 

Guengerich, F.P (2002) Cytochrome P450 enzymes in the generation of commercial products. Nature Reviews. Drug Discovery, 1, 359-366. 

Khosla, C. and Keasling, J.D. (2003) Metabolic engineering for drug discovery and development. Nature Reviews. Drug Discovery, 2, 1019. 

Frokjaer, S and Otzen, D. 2005. Protein drug stability a formulation challenge. Nature Reviews Drug Discovery 4(4), 298-306. 

Schrama, D., Reisfeld, R.A., and Becker, J.C. 2006. Antibody targeted drugs as cancer therapeutics. Nature Reviews Drug Discovery 5(2), 147-159. 

Frantz, S. (2006) Pipeline problems are increasing the urge to merge. Nature Reviews. Drug Discovery, 5, 977-979. Owens, J. (2007) 2006 drug approvals finding the niche. Nature Reviews. Drug Discovery, 6, 99-101. 

Hopkins, A.L. and Groom, C.R. (2002) The druggable genome. Nature Reviews Drug discovery, 1, 727-730. 

Bleicher, K.H., Bohm, H.J., Muller, K. and Alanine, A.I. (2003) Hit and lead generation beyond high-throughput screening. Nature Reviews Drug Discovery, 2, 369-378. 

Cohen, P. (2002) Protein kinases - the major drug targets of the twenty-first century Nature Reviews Drug Discovery, 1, 309-315. 

Roth, B.L., Sheffler, D.J. and Kroeze, W.K. (2004) Magic shotguns versus magic bullets selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews. Drug Discovery, 3 (4), 353-359. 

O Connor, K.A. and Roth, B.L. (2005) Finding new tricks for old drugs an efficient route for public-sector drug discovery. Nature Reviews. Drug Discovery, 4 (12), 1005-1014. 

Wienkers, L.C. and Heath, T.G. (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews. Drug Discovery, 4 (10), 825—833. 

Van de Waterbeemd H. Gifford E. ADMET in silico modelling Towards prediction paradise Nature Reviews Drug Discovery, 2003, 2 (3), 192-204. 

Sources (1) Campbell MK, Farrell SO. Biochemistry, 5th ed., Thomson Brooks/Cole, Belmont, CA, 2006. (2) Vousden KH, Lane DP. p53 in health and disease, Nature Reviews Molecular Cell Biology 8 275-283 (2007). (3) Kirkpatrick P. Unleashing p53,Nature Reviews Drug Discovery 3 111 (2004). 

Imming P, Sinning C, Meyer A. Opinion drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery 5 821-834 (2006). 

Example of the use of NMR to design inhibitors. (Source Pellecchia M, Sem DS, Wuthrich K. NMR in drug discovery. Nature Reviews Drug Discovery 1 211-219 (2002). Used with permission.)... 

Source Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics basic principles and recent applications, Nature Reviews Drug Discovery 1 503-514 (2002). 

Agranat I, Caner H, Caldwell J. Putting chirality to work the strategy of chiral switches, Nature Reviews Drug Discovery 1 753-768 (2002). 

Blundell TL, Jhoti H, Abell C. High-throughput crystallography for lead discovery in drug design, Nature Reviews Drug Discovery 1 45-54 (2002). 

Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery methods and applications. Nature Reviews Drug Discovery 3 935-949 (2004). 

Kitano H. A robustness-based approach to systems-oriented drug design. Nature Reviews Drug Discovery 6 202-210 (2007). 

Schneider G, Fechner U. Computer-based de novo design of drug-like molecules, Nature Reviews Drug Discovery 4 649-663 (2005). 

Development trends for monoclonal antibody cancer therapeutics, Nature Reviews Drug Discovery 6 340-356... 

---